No Data
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Recently obtained 30 overseas qualification certifications.
On March 25, Glonghui reported that Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced that the company and its subsidiaries recently obtained 30 overseas certification qualifications. The acquisition of these qualifications has enriched the variety of the company's products, further improved the menu of the company's in vitro diagnostic products, and actively responded to the demands of the overseas market, facilitating the enhancement of the company's market expansion capabilities and strengthening its core competitiveness.
Express News | Sungen Biomedical's World-First New Drug Sgc001 Monoclonal Antibody Receives FDA Fast Track Approval
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Net loss of 86.5829 million yuan for the year 2024.
Gelonghui, February 27, Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced its performance report for the year 2024. During the reporting period, the company achieved a total operating revenue of 1,806.3115 million yuan, a decrease of 9.96% year-on-year; the net income attributable to the parent company's owners was -86.5829 million yuan, a decrease of 199.92% year-on-year; the net income attributable to the parent company's owners after deducting non-recurring gains and losses was -106.2866 million yuan, a decrease of 232.18% year-on-year.
Beijing Hotgen Biotech Co., Ltd (688068.SH): plans to carry out a non-proportional capital reduction for Yujing Pharmaceuticals together with Lin Changqing and Yaojing Partners.
On February 17, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that it convened the 26th meeting of the third Board of Directors on February 14, 2025, to review and approve the proposal regarding the reduction of capital and related transactions of its holding subsidiary. Beijing Hotgen plans to conduct a non-proportional capital reduction for its holding subsidiary Yujing Pharmaceutical with Mr. Lin Changqing and Yaojing Partnership, reducing the registered capital by a total of 20 million yuan. After this capital reduction is completed, Yujing Pharmaceutical's capital will decrease from the original 50 million yuan to 30 million yuan. The company holds 58% equity in Yujing Pharmaceutical, which remains a holding subsidiary of the company.